ProKidney - Kapitalisasi Buku PROK

ProKidney Corp. (PROK) delegates drug manufacturing and testing to third-party contractors, utilizing global logistics for distribution. The current financial status is characterized by a liquidity deficit and the depletion of reserves due to costly R&D in the absence of revenue, which is recorded at -0.88. This price chart illustrates the dynamics of an asset whose technologies rely on automated bioreactors to create personalized therapies without the risk of contamination.

PROK Kapitalisasi Buku ProKidney Pharma (28.04.2023 - 27.10.2026)

Rincian metrik lan analitis perusahaan ProKidney (PROK)

- rega lan prakiraan konsensus rega:

Rega bursa ProKidney Pharma|PROK - Bagan rega target

- data kapitalisasi pasar:

Kapitalisasi pasar ProKidney Corp|PROK - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Buku Saham ProKidney|PROK - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku prokidney.com|PROK - Total Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal ProKidney Corp.|PROK - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal ProKidney Corp|PROK - Utang perusahaan|Utang marang nilai buku ProKidney Corp

Pambiji fundamental:PROK - ProKidney Pharma

Book value capitalization determines the intrinsic value of a business through the difference between all assets and liabilities. This calculation reveals the actual amount of equity available to shareholders. The trend in the firm's book capitalization reflects the rate of change in net assets in real-time. For ProKidney Corp. (PROK), this is a critical metric demonstrating the cash burn rate for R&D. The declining trend confirms a lack of revenue amid high clinical trial expenditures.

Analisis pesaing ProKidney Corp.